Preclinical study design for evaluation of stem cell-derived cellular therapy products

A pathologist's perspective

Julia F M Baker, Basel Assaf

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Despite - or perhaps because of - the rapid expansion of interest in stem cell-derived cellular therapy products, relatively few guidelines have been published to assist in the design of scientifically sound preclinical studies. The field is complex and wide ranging, and of necessity regulators tend to treat each project on a case by case basis. One of the core tenets remains the need to retain all tissues from the study, thereby allowing for further analysis of tissues should unexpected effects be seen in clinical studies; attempts to comply with this may result in an unmanageable financial burden. Judicious input from the pathologist at the earliest stages of study design may not only improve the scientific integrity of the study but also help to mitigate some of the cost. Careful animal selection, the development of robust cell markers, and justifiable triage of tissues based on phased tissue examination can all be discussed with the regulatory authorities at pre-pre-investigational new drug (IND) and pre-IND meetings to achieve optimal study design.

Original languageEnglish (US)
Pages (from-to)126-131
Number of pages6
JournalToxicologic Pathology
Volume43
Issue number1
DOIs
StatePublished - Jan 30 2015

Fingerprint

Stem cells
Stem Cells
Tissue
Investigational Drugs
Triage
Therapeutics
Animals
Acoustic waves
Guidelines
Costs and Cost Analysis
Pathologists
Costs

Keywords

  • cell therapy
  • preclinical
  • stem cell
  • study design

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Toxicology
  • Cell Biology
  • Molecular Biology

Cite this

Preclinical study design for evaluation of stem cell-derived cellular therapy products : A pathologist's perspective. / Baker, Julia F M; Assaf, Basel.

In: Toxicologic Pathology, Vol. 43, No. 1, 30.01.2015, p. 126-131.

Research output: Contribution to journalArticle

@article{f9904e1368ee4977a6211bd0f4a313cf,
title = "Preclinical study design for evaluation of stem cell-derived cellular therapy products: A pathologist's perspective",
abstract = "Despite - or perhaps because of - the rapid expansion of interest in stem cell-derived cellular therapy products, relatively few guidelines have been published to assist in the design of scientifically sound preclinical studies. The field is complex and wide ranging, and of necessity regulators tend to treat each project on a case by case basis. One of the core tenets remains the need to retain all tissues from the study, thereby allowing for further analysis of tissues should unexpected effects be seen in clinical studies; attempts to comply with this may result in an unmanageable financial burden. Judicious input from the pathologist at the earliest stages of study design may not only improve the scientific integrity of the study but also help to mitigate some of the cost. Careful animal selection, the development of robust cell markers, and justifiable triage of tissues based on phased tissue examination can all be discussed with the regulatory authorities at pre-pre-investigational new drug (IND) and pre-IND meetings to achieve optimal study design.",
keywords = "cell therapy, preclinical, stem cell, study design",
author = "Baker, {Julia F M} and Basel Assaf",
year = "2015",
month = "1",
day = "30",
doi = "10.1177/0192623314556515",
language = "English (US)",
volume = "43",
pages = "126--131",
journal = "Toxicologic Pathology",
issn = "0192-6233",
publisher = "SAGE Publications Inc.",
number = "1",

}

TY - JOUR

T1 - Preclinical study design for evaluation of stem cell-derived cellular therapy products

T2 - A pathologist's perspective

AU - Baker, Julia F M

AU - Assaf, Basel

PY - 2015/1/30

Y1 - 2015/1/30

N2 - Despite - or perhaps because of - the rapid expansion of interest in stem cell-derived cellular therapy products, relatively few guidelines have been published to assist in the design of scientifically sound preclinical studies. The field is complex and wide ranging, and of necessity regulators tend to treat each project on a case by case basis. One of the core tenets remains the need to retain all tissues from the study, thereby allowing for further analysis of tissues should unexpected effects be seen in clinical studies; attempts to comply with this may result in an unmanageable financial burden. Judicious input from the pathologist at the earliest stages of study design may not only improve the scientific integrity of the study but also help to mitigate some of the cost. Careful animal selection, the development of robust cell markers, and justifiable triage of tissues based on phased tissue examination can all be discussed with the regulatory authorities at pre-pre-investigational new drug (IND) and pre-IND meetings to achieve optimal study design.

AB - Despite - or perhaps because of - the rapid expansion of interest in stem cell-derived cellular therapy products, relatively few guidelines have been published to assist in the design of scientifically sound preclinical studies. The field is complex and wide ranging, and of necessity regulators tend to treat each project on a case by case basis. One of the core tenets remains the need to retain all tissues from the study, thereby allowing for further analysis of tissues should unexpected effects be seen in clinical studies; attempts to comply with this may result in an unmanageable financial burden. Judicious input from the pathologist at the earliest stages of study design may not only improve the scientific integrity of the study but also help to mitigate some of the cost. Careful animal selection, the development of robust cell markers, and justifiable triage of tissues based on phased tissue examination can all be discussed with the regulatory authorities at pre-pre-investigational new drug (IND) and pre-IND meetings to achieve optimal study design.

KW - cell therapy

KW - preclinical

KW - stem cell

KW - study design

UR - http://www.scopus.com/inward/record.url?scp=84921784968&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921784968&partnerID=8YFLogxK

U2 - 10.1177/0192623314556515

DO - 10.1177/0192623314556515

M3 - Article

VL - 43

SP - 126

EP - 131

JO - Toxicologic Pathology

JF - Toxicologic Pathology

SN - 0192-6233

IS - 1

ER -